Cell cycle arrest and apoptosis are early events in radiosensitization of EWS::FLI1+ Ewing sarcoma cells by Mithramycin A.
暂无分享,去创建一个
[1] Xianqun Fan,et al. Promoting reactive oxygen species generation: a key strategy in nanosensitizer-mediated radiotherapy. , 2021, Nanomedicine.
[2] T. Damron,et al. Mithramycin A radiosensitizes EWS:Fli1+ Ewing sarcoma cells by inhibiting double strand break repair. , 2020, International journal of radiation oncology, biology, physics.
[3] Gabrielle E Foxa,et al. Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor , 2020, EMBO molecular medicine.
[4] Chuong D. Hoang,et al. UHRF1 is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] D. Venzon,et al. Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters , 2019, Molecular Pharmacology.
[6] P. Houghton,et al. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force , 2019, F1000Research.
[7] Zhongmei Zhou,et al. Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1 , 2018, Scientific Reports.
[8] S. Lessnick,et al. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma , 2017, PloS one.
[9] L. Helman,et al. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript , 2017, Cancer Chemotherapy and Pharmacology.
[10] Hongmei Gao,et al. Mithramycin inhibits epithelial-to-mesenchymal transition and invasion by downregulating SP1 and SNAI1 in salivary adenoid cystic carcinoma , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[11] Jingxi Ma,et al. Prdx6 Upregulation by Curcumin Attenuates Ischemic Oxidative Damage via SP1 in Rats after Stroke , 2017, BioMed research international.
[12] A. Astudillo,et al. Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma , 2016, Oncotarget.
[13] T. Das,et al. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin. , 2015, Translational research : the journal of laboratory and clinical medicine.
[14] Mark Girolami,et al. EWS-FLI1 employs an E2F switch to drive target gene expression , 2015, Nucleic acids research.
[15] Eun-Sun Choi,et al. Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer , 2014, Scientific Reports.
[16] H. Kovar. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy , 2014, Expert opinion on therapeutic targets.
[17] P. Meltzer,et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer , 2013, Genome research.
[18] S. Chopde. Fortified foods for combat with malnutrition , 2013 .
[19] S. Blacher,et al. Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors , 2013, PloS one.
[20] K. Ross,et al. The Biology of Ewing Sarcoma , 2013, ISRN oncology.
[21] S. Safe,et al. Mithramycin A Inhibits Myeloid Cell Leukemia-1 to Induce Apoptosis in Oral Squamous Cell Carcinomas and Tumor Xenograft through Activation of Bax and Oligomerization , 2013, Molecular Pharmacology.
[22] K. Ishige,et al. Neuroprotective effect of mithramycin against endoplasmic reticulum stress-induced neurotoxicity in organotypic hippocampal slice cultures , 2011, Neuropharmacology.
[23] Qing-Rong Chen,et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. , 2011, Journal of the National Cancer Institute.
[24] Kiyoko Kato,et al. Low‐dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin‐3 in gynecologic cancers , 2010, Cancer science.
[25] P. Meltzer,et al. A Molecular Function Map of Ewing's Sarcoma , 2009, PloS one.
[26] Nicolò Riggi,et al. The Biology of Ewing sarcoma. , 2007, Cancer letters.
[27] S. Elmore. Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.
[28] A. I. Rojo,et al. Regulation of heme oxygenase-1 gene expression through the phosphatidylinositol 3-kinase/PKC-zeta pathway and Sp1. , 2006, Free radical biology & medicine.
[29] G. Laurent,et al. Mithramycin A activates Fas death pathway in leukemic cell lines , 2006, Apoptosis.
[30] Y. Iwamoto,et al. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors , 2005, International journal of cancer.
[31] Y. Iwamoto,et al. Transactivation of cyclin E gene by EWS‐Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells , 2005, International journal of cancer.
[32] T. Cotter,et al. The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF) , 2004, British Journal of Cancer.
[33] M. Pfaffl,et al. A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.
[34] K. Tanaka,et al. Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G 1 regulatory genes , 2001, British Journal of Cancer.
[35] L. Kuhns,et al. Effects of radiation therapy on growing long bones. , 1976, AJR. American journal of roentgenology.
[36] A. Cheong,et al. K(v)1.5 potassium channel gene regulation by Sp1 transcription factor and oxidative stress. , 2007, American journal of physiology. Heart and circulatory physiology.